Supplementation in Adolescent Girls With Endometriosis (SAGE)
Primary Purpose
Endometriosis
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Vitamin D3
Fish Oil
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Endometriosis focused on measuring Adolescent, Endometriosis, Diet, Nutrition, Pain
Eligibility Criteria
Inclusion Criteria:
- Female
- Age 12 years -25 years
- Previously surgically diagnosed at Boston Children's Hospital with endometriosis
- At least 6 weeks following laparoscopy
- Minimum pain score within the 4 weeks preceding study baseline
- Must be able to swallow an empty 00 gelatin capsule at baseline
- Must be willing to stop all vitamins and nutritional supplements during trial
Exclusion Criteria:
- Concurrent chronic illnesses that affect gastrointestinal absorption of nutrients (e.g., celiac disease, IBD, cystic fibrosis)
- Vitamin D level of greater than or equal to 100 ng/ml at study baseline
- History of renal stones
- No access to text messages or email
- Pregnancy
- Non-English speaking
Sites / Locations
- Boston Children's Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
Vitamin D
Fish Oil
Placebo
Arm Description
Vitamin D3 2000 IU daily taken for 6 months
Fish Oil 1000 mg daily for 6 months
Placebo taken daily for 6 months.
Outcomes
Primary Outcome Measures
Endometriosis pain
Measured by change in the score of the visual analog scale (VAS) from baseline to 6 months.
Secondary Outcome Measures
Quality of life
Measured by change in SF-36 and EPHect questionnaires from baseline to 6 months.
Pain medication usage
Measured via questionnaire of medication usage from baseline to 6 months.
Full Information
NCT ID
NCT02387931
First Posted
May 29, 2013
Last Updated
November 30, 2016
Sponsor
Boston Children's Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02387931
Brief Title
Supplementation in Adolescent Girls With Endometriosis
Acronym
SAGE
Official Title
SAGE: Supplementation in Adolescent Girls With Endometriosis
Study Type
Interventional
2. Study Status
Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
September 2014 (undefined)
Primary Completion Date
July 2016 (Actual)
Study Completion Date
July 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Boston Children's Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine whether dietary supplementation with Vitamin D or Fish Oil can help to reduce physical and emotional symptoms in adolescent girls with endometriosis.
Detailed Description
This is a randomized controlled trial designed to evaluate the effect of dietary supplementation on endometriosis symptom remediation. Adolescent and young adults females aged 12 to 25 years with a surgically-confirmed diagnosis of endometriosis will be eligible for study participation. Subjects will be excluded if they have concurrent chronic illnesses that affect gastrointestinal absorption of nutrients (e.g., celiac disease, IBD, cystic fibrosis), a history of renal stones, are pregnant, or non-English speaking. Once consented, subjects will be randomized to one of 3 treatment assignments: 1) vitamin D3 2000 IU daily (n=30), 2) fish oil 1000 mg daily (n=30), 3) placebo (n=30) and will take these daily for 6 months. Baseline nutrient intake from food and supplements will be assessed using the Food Frequency Questionnaire (FFQ). The 142 item survey assesses usual dietary intake during the past year. Validated rating scales including the visual analog scale (VAS), SF-36, and the World Endometriosis EPHect questionnaires will be used to measure pain and overall quality of life. The SF-36 measures 8 health concepts relevant across disease groups, including limitations to physical or social activities because of health problems, vitality, and general health perception. Patients will complete a full review of medication usage, past medical history, family history, and other lifestyle factors. Anthropometrics will be measured, and vital signs obtained. Measures will be repeated at 3-month intervals for a total of 6 months. Blood will be drawn at baseline, and at 6 months to measure levels of fatty acids, vitamin D, parathyroid hormone (PTH), and calcium.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endometriosis
Keywords
Adolescent, Endometriosis, Diet, Nutrition, Pain
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
69 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Vitamin D
Arm Type
Experimental
Arm Description
Vitamin D3 2000 IU daily taken for 6 months
Arm Title
Fish Oil
Arm Type
Experimental
Arm Description
Fish Oil 1000 mg daily for 6 months
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo taken daily for 6 months.
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin D3
Other Intervention Name(s)
Nature Made Vitamin D 2000IU Liquid softgels
Intervention Description
Nature Made Vitamin D 2000IU, 1 softgel taken daily
Intervention Type
Dietary Supplement
Intervention Name(s)
Fish Oil
Other Intervention Name(s)
Nature Made ultra omega-3 mini fish oil 500mg, 2 daily
Intervention Description
Nature Made ultra omega-3 mini fish oil 500mg, 2 soft gels taken daily
Intervention Type
Other
Intervention Name(s)
Placebo
Other Intervention Name(s)
Placebo capsule
Intervention Description
Placebo capsule, 2 taken daily
Primary Outcome Measure Information:
Title
Endometriosis pain
Description
Measured by change in the score of the visual analog scale (VAS) from baseline to 6 months.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Quality of life
Description
Measured by change in SF-36 and EPHect questionnaires from baseline to 6 months.
Time Frame
6 months
Title
Pain medication usage
Description
Measured via questionnaire of medication usage from baseline to 6 months.
Time Frame
6 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female
Age 12 years -25 years
Previously surgically diagnosed at Boston Children's Hospital with endometriosis
At least 6 weeks following laparoscopy
Minimum pain score within the 4 weeks preceding study baseline
Must be able to swallow an empty 00 gelatin capsule at baseline
Must be willing to stop all vitamins and nutritional supplements during trial
Exclusion Criteria:
Concurrent chronic illnesses that affect gastrointestinal absorption of nutrients (e.g., celiac disease, IBD, cystic fibrosis)
Vitamin D level of greater than or equal to 100 ng/ml at study baseline
History of renal stones
No access to text messages or email
Pregnancy
Non-English speaking
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stacey A Missmer, ScD
Organizational Affiliation
Department of Reproductive Medicine, Brigham and Women's Hospital and Harvard Medical School
Official's Role
Principal Investigator
Facility Information:
Facility Name
Boston Children's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
32453393
Citation
Nodler JL, DiVasta AD, Vitonis AF, Karevicius S, Malsch M, Sarda V, Fadayomi A, Harris HR, Missmer SA. Supplementation with vitamin D or omega-3 fatty acids in adolescent girls and young women with endometriosis (SAGE): a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2020 Jul 1;112(1):229-236. doi: 10.1093/ajcn/nqaa096.
Results Reference
derived
Learn more about this trial
Supplementation in Adolescent Girls With Endometriosis
We'll reach out to this number within 24 hrs